NASDAQ · KRYS
Krystal Biotech, Inc.
$324.55+$3.13 (+0.97%)
Krystal Biotech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.16% below the high.
Loading market information…
NASDAQ · MGTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
MeiraGTx Holdings plc’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.46. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow MeiraGTx Holdings plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$0.51-34.21% vs estimate | $1.93M-56.62% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$0.50-4.17% vs estimate | $21.39M+1,326.0% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.54-14.89% vs estimate | $10.91M+573.46% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $21.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$324.55+$3.13 (+0.97%)
Krystal Biotech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.16% below the high.
$13.23-$0.09 (-0.68%)
Intellia Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.41% below the high.
$25.30+$0.33 (+1.32%)
uniQure N.V.’s quoted price sits in the lower half of its reported 52-week range, 63.85% below the high.
$2.72+$0.09 (+3.42%)
Sana Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.99% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$7.41+$0.17 (+2.35%)
REGENXBIO Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.23% below the high.
$1.03-$0.01 (-0.96%)
Lineage Cell Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
